Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment

The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Murayama, Aiko, Tajiri, Kazuto, Nakaya, Atsuko, Ito, Hiroyuki, Hayashi, Yuka, Entani, Toshiki, Nagata, Kohei, Tanaka, Shinichi, Hamashima, Takeru, Yasuda, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case and Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454244/
https://www.ncbi.nlm.nih.gov/pubmed/34616270
http://dx.doi.org/10.1159/000516199
_version_ 1784570448131915776
author Murayama, Aiko
Tajiri, Kazuto
Nakaya, Atsuko
Ito, Hiroyuki
Hayashi, Yuka
Entani, Toshiki
Nagata, Kohei
Tanaka, Shinichi
Hamashima, Takeru
Yasuda, Ichiro
author_facet Murayama, Aiko
Tajiri, Kazuto
Nakaya, Atsuko
Ito, Hiroyuki
Hayashi, Yuka
Entani, Toshiki
Nagata, Kohei
Tanaka, Shinichi
Hamashima, Takeru
Yasuda, Ichiro
author_sort Murayama, Aiko
collection PubMed
description The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury has been shown refractory to steroid treatment. This study describes 2 patients with hepatic irAEs manifesting as intrahepatic bile duct injury. Immunostaining with antibodies to both CD8 and cytokeratin-7 was useful for the diagnosis, and both patients were refractory to steroid treatment. Prompt diagnosis and active immunosuppressive therapies are required in such cases.
format Online
Article
Text
id pubmed-8454244
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-84542442021-10-05 Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment Murayama, Aiko Tajiri, Kazuto Nakaya, Atsuko Ito, Hiroyuki Hayashi, Yuka Entani, Toshiki Nagata, Kohei Tanaka, Shinichi Hamashima, Takeru Yasuda, Ichiro Case Rep Gastroenterol Case and Review The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury has been shown refractory to steroid treatment. This study describes 2 patients with hepatic irAEs manifesting as intrahepatic bile duct injury. Immunostaining with antibodies to both CD8 and cytokeratin-7 was useful for the diagnosis, and both patients were refractory to steroid treatment. Prompt diagnosis and active immunosuppressive therapies are required in such cases. S. Karger AG 2021-07-13 /pmc/articles/PMC8454244/ /pubmed/34616270 http://dx.doi.org/10.1159/000516199 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case and Review
Murayama, Aiko
Tajiri, Kazuto
Nakaya, Atsuko
Ito, Hiroyuki
Hayashi, Yuka
Entani, Toshiki
Nagata, Kohei
Tanaka, Shinichi
Hamashima, Takeru
Yasuda, Ichiro
Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title_full Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title_fullStr Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title_full_unstemmed Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title_short Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
title_sort intrahepatic bile duct injury as a hepatic immune-related adverse event after immune-checkpoint inhibitor treatment
topic Case and Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454244/
https://www.ncbi.nlm.nih.gov/pubmed/34616270
http://dx.doi.org/10.1159/000516199
work_keys_str_mv AT murayamaaiko intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT tajirikazuto intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT nakayaatsuko intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT itohiroyuki intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT hayashiyuka intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT entanitoshiki intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT nagatakohei intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT tanakashinichi intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT hamashimatakeru intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment
AT yasudaichiro intrahepaticbileductinjuryasahepaticimmunerelatedadverseeventafterimmunecheckpointinhibitortreatment

Ejemplares similares